Microbicide Trials Network

• (http://twitter.com/share) From despair to hope

[allAfrica.com] What makes a young African doctor decide to devote her career to helping women fight HIV? Dr. Sengeziwe Sibeko is a 37-year-old medical researcher with a degree in obstetrics and gynecology from the University of KwaZulu Natal (UKZN) in South Africa, an MSc in epidemiology from Columbia University in the United States, and is about to take up a fellowship to study for her PhD at ...

[allAfrica.com] Durban, South Africa - Africans tracking the worldwide HIV epidemic have not found much to celebrate since Aids began ravaging the continent 30 years ago, but researchers are optimistic that they are learning as much from their failures as their successes.

NEW YORK, Feb. 1, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Antiviral Therapeutics - Technologies, markets and companies http://www.reportlinker.com/p0203535/Antiviral-Therapeutics---Technologies-markets-and-companies.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=TherapyThis ...

LONDON, Jan. 30 2012 /PRNewswire/ -- Today Johnson & Johnson joined the World Health Organization (WHO), 12 other pharmaceutical companies, the Bill & Melinda Gates Foundation, the U.S. and U.K. governments, ...

This post in the Malaria Free Future blog reports on a study underway in Rwanda that aims to measure the prevalence of malaria in pregnancy (MIP).

Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Viread in combination with other antiretroviral agents for the treatment of HIV-1 infection in pediatric patients ages 2-12.

VICTORIA, British Columbia and DALLAS , January 18, 2012 /PRNewswire/ --UNIT4 Business Software ( http://www.unit4software.com ), the North American subsidiary of UNIT4, the world's leading provider of ...

ViroPharma Incorporated today announced that Health Canada has granted the company Priority Review status for its New Drug Submission (NDS) for Cinryze (C1 inhibitor [human]).

Rwanda is expanding its medical male circumcision program this year, "as the country attempts to reach its goal of medically circumcising 50 percent of men by June 2013 as part of HIV prevention efforts," PlusNews reports.

NEW YORK , Dec. 29, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Antiviral Therapeutics - Technologies, markets and companies http://www.reportlinker.com/p0203535/Antiviral-Therapeutics---Technologies-markets-and-companies.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=TherapySummaryThis ...

This story originally ran on Dec. 22. A team led by researchers at the University of California, San Francisco, has identified a family of amyloidogenic peptides in semen that may significantly enhance HIV infection.

An announcement by Canadian scientists, stating that a breakthrough in the search for a HIV/AIDS vaccine was close at hand, has generated excitement.

Isentress (raltegravir) was approved today by the U.S. Food and Drug Administration for use with other antiretroviral drugs for the treatment of HIV-1 infection for children and adolescents ages 2-18.

It's not a matter of if a worldwide pandemic will strike but when, say experts like veterinarian and epidemiologist Jonna Mazet, a professor in the Department of Medicine and Epidemiology in the University of California, Davis, School of Veterinary Medicine. That's why Mazet, who leads an early warning pandemic system called PREDICT, monitors the world's hot spots, or "hot interfaces" for signs ...

Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received approval for three antiretroviral (ARV) therapies used to treat HIV/AIDS under the World Health Organization's (WHO) Prequalification of Medicines Programme. The products include:

The worldwide AIDS epidemic makes research on HIV, the disease processes it induces, and potential HIV therapies among the most critical in biomedical science. Furthermore, the basic biology of HIV infections provides a model for a more general understanding of retroviruses and their hosts.

Scientists have discovered new protein fragments in semen that enhance the ability of HIV, the virus that causes AIDS, to infect new cells -- a discovery that one day could help curb the global spread of this deadly pathogen.

Scientists at the Gladstone Institutes have discovered new protein fragments in semen that enhance the ability of HIV, the virus that causes AIDS, to infect new cells—a discovery that one day could help curb the global spread of this deadly pathogen.

Scientists at the Gladstone Institutes have discovered new protein fragments in semen that enhance the ability of HIV, the virus that causes AIDS, to infect new cells -- a discovery that one day could help curb the global spread of this deadly pathogen.